Product Details
| Product Name:
LY3372689 |
CAS No.:
2241514-56-5 |
| Purity:
99.50% |
Supply Ability:
10g |
| Release date:
2026/06/08 |
Product Introduction
Bioactivity
| Name | LY3372689 |
| Description | LY3372689 (Formulaic Ia) is an oral, highly selective, CNS-permeable O-GlcNAcase (OGA) inhibitor. LY3372689 exerts a neuroprotective effect by inhibiting OGA enzymatic activity, increasing the O-GlcNAc glycosylation level of tau protein, and thereby reducing abnormal tau phosphorylation and the formation of neurofibrillary tangles. LY3372689 can be used in research on tau-related diseases, including Alzheimer’s disease. |
| In vitro | Methods: 300-μm-thick mouse hippocampal slices were treated with 10 μM LY3372689 or DMSO for 4 h. Whole-cell patch-clamp recordings were performed on CA1 neurons to assess paired-pulse facilitation (PPF) and paired-pulse depression (PPD).
Results: LY3372689 significantly reduced PPF and PPD, impairing short-term synaptic plasticity. [3] |
| In vivo | Methods: Sprague Dawley rats were administered a single oral dose of 0.001–3 mg/kg. Plasma concentrations and enzyme occupancy rates were measured post-administration.
Results: The highest dose group treated with LY3372689 achieved over 90% EO and a maximum OGA enzyme occupancy of 98%. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 225 mg/mL (586.79 mM), Sonication is recommended.
|
| Keywords | tau | O-GlcNAcase | MicrotubuleAssociated | Microtubule Associated | LY-3372689 | LY3372689 | LY 3372689 |
| Inhibitors Related | Flubendazole | N-Phenylbenzylamine | Mebendazole | 4-Isopropoxybenzoic acid | Pregnenolone acetate | Oxfendazole | α-Cyclodextrin | Methylene Blue trihydrate | 2-Methylthiophenothiazine | Paclitaxel | 4'-Demethylepipodophyllotoxin | Albendazole |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Bioactive Compound Library Plus | Microtubule-Targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Cytoskeletal Signaling Pathway Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States